Developing a portfolio of first-in-class immune-oncology antibodies (On Demand)

What does it take to develop a portfolio of immune-oncology candidates? In this fireside chat, Dr. Tom Burt, Sofinnova Partners SAS, will discuss the strategies needed and the path to building a world-class immuno-oncology biotech, along with Dr. Martin Welschof and experts Drs. Christine Power and Björn Cochlovius. During the session, Dr. Welschof, CEO of BioInvent, a clinical-stage company based in Sweden that is developing immuno-modulatory antibodies for the treatment of cancer, and the panel will detail their experiences of the many facets that contribute to building an innovative clinical stage antibody enterprise, including antibody discovery, clinical development, partnership, manufacturing and finance.

Seminar Information
Date Presented:
November 23, 2021 11:00 AM Eastern
Length:
1 hour
Register Now
First Name:
Last Name:
Email:
Confirm Email:
Organization:
Country:
Product:
On-Demand
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Developing a portfolio of first-in-class immune-oncology antibodies

What does it take to develop a portfolio of immune-oncology candidates? In this fireside chat, Dr. Tom Burt, Sofinnova Partners SAS, will discuss the strategies needed and the path to building a world-class immuno-oncology biotech, along with Dr. Martin Welschof and experts Drs. Christine Power and Björn Cochlovius. During the session, Dr. Welschof, CEO of BioInvent, a clinical-stage company based in Sweden that is developing immuno-modulatory antibodies for the treatment of cancer, and the panel will detail their experiences of the many facets that contribute to building an innovative clinical stage antibody enterprise, including antibody discovery, clinical development, partnership, manufacturing and finance.

Speaker Information
Thomas Burt  [ view bio ]
Bjoern Cochlovius  [ view bio ]
Christine Power  [ view bio ]
Martin Welschof  [ view bio ]
Individual topic purchase: Selected